=== Outcome Extract 1 (Outcome) ===
irgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome.
Oncology 2005;69 Suppl 2:2-7.
αρχική εκτίμηση και η περιοδική παρακολούθηση της οστικής μάζας με Dexa scan στην ΟΜΣΣ, το ισχίο (αυχένα
διατροφικών συμπληρωμάτων), είναι τουλάχιστον 1000 mg για άνδρες ηλικίας 19 έως 70 ετών και 1200 mg
ανά ημέρα για άνδρες ηλικίας 71 ετών και άνω και για τις μετεμμ

=== Outcome Extract 2 (Effect) ===
sumab αποτελεί μια ενδεδειγμένη θεραπευτική επιλογή για τους ασθενείς με οστικές
μεταστάσεις (I, B).
1. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in
postmenopausal women. JAMA 2002;288:2300–2306.
2. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone
density in men and women 65 years of age or older. N Engl J Med 1997;337:670– 676.
3. National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: calcium.
Available at:  od.nih.gov/factsheets/calcium.asp. Accessed May

=== Outcome Extract 3 (Effect) ===
. Am J Psychiatry 1983; 140:1048.
Row 4: 5. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in

=== Outcome Extract 4 (Efficacy) ===
Sep 28
solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi:
10.1016/S1470-2045(19)30691-6,PMID: 31838007; PMCID: PMC7461630.
110. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried
M, Diaz LA Jr et al, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite
Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H,

=== Outcome Extract 5 (Efficacy) ===
he Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠ

=== Outcome Extract 6 (Efficacy) ===
νοθεραπεία.
Σημείωση: O συνδυασμός Doxorubicin και Trabectedin στη θεραπεία πρώτης γραμμής βρέθηκε ότι αυξάνει σημαντικά i. Fulvestrant
ii. Megestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θε

=== Outcome Extract 7 (Efficacy) ===
–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015 Jun;26(6):1081-90.
5. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year
review of efficacy and safety. Oncologist. 20 Apr;20(4):450-458.
6. Antiemesis, NCCN guidelines, version 4.2020 at:
7. SANCUSO περίληψη χαρακτηριστικών προϊόντος
8. Larkin et al, Diagnosis, assessment and management of constipation in advanced cancer ESMO clinical
practice guidelines Annals of Oncology 29 (Supplement

=== Outcome Extract 8 (Efficacy) ===
our years of experience,
. 2010 Jun; 56(6): 514–517
4. Khanna I, Pillarisetti S, Buprenorphine – an attractive opioid with underutilized potential in treatment of
chronic pain, Journal of pain research, volume 2015: 8 pages 859-870.
5. Raffa R, Ding Z.,Examination of the preclinical antinociceptive efficacy of buprenorphine and its
designation as full- or partial-agonist, Acute Pain2007;145-152.
6. Pergolizzi J, Aloisi AM, Filitz J, Langford R, Likar R, Mercadante S et al, Current Knowledge of
Buprenorphine and Its Unique Pharmacological Profile, Pain Practice 2010; 10; 428-450.
7. Virk Ms, Arttamangl

=== Outcome Extract 9 (Efficacy) ===
insworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel for larynx pr

=== Outcome Extract 10 (Efficacy) ===
n
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the
Row 10: management of delirium: A comparison of efficacy, safety, and side effects. Palliat Support Care. 2015 Row 1: Νόσημα|Εμπορική ονομασία εμβολίου|Σύσταση|Χρονισμός|Παρατηρήσεις
Row 2: Γρι�πη|Fluarix, Influvac, Vaxigrip Fulcelvax, Fluad, Efluelda|Ετη�σιος εμβολιασμο�ς για ο�λους. Δυνητικα� με “ενισχυμε�νο” εμβο�λιο για τους 65 ετω�ν και α�νω|Αρχε�ς

=== Outcome Extract 11 (Safety) ===
EYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠΕΙΑ ΣΥΝΤΗΡΗ

=== Outcome Extract 12 (Safety) ===
ημείωση: O συνδυασμός Doxorubicin και Trabectedin στη θεραπεία πρώτης γραμμής βρέθηκε ότι αυξάνει σημαντικά i. Fulvestrant
ii. Megestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θεραπευτικό π

=== Outcome Extract 13 (Safety) ===
ed, Fleming, ID, Cooper, JS,
Henson, DE, et al (Eds), Lippincott-Raven, Philadelphia, 1997. p 241.
2. Bajorin, M.D., J. Witjes, M.D., Gschwend et al: Adjuvant Nivolumab versus Placebo in Muscle-Invasive
Urothelial Carcinoma. N Engl J Med 2021; 384:2102-2114
3. Apolo AB, Infante JR, Hamid O, et al: Safety, clinical activity, and PD-L1 expression of avelumab
(MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the
JAVELIN Solid Tumor phase Ib trial. JCO Abstract Ε1ν. δεIpίξiεlιiςm: Σuτmάaδbια ΙΙb, IIc και ΙΙΙ (κατά AJCC)
Η έγκριση του είναι σε δόση 10mg/kgx4 δό

=== Outcome Extract 14 (Safety) ===
an K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015 Jun;26(6):1081-90.
5. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year
review of efficacy and safety. Oncologist. 20 Apr;20(4):450-458.
6. Antiemesis, NCCN guidelines, version 4.2020 at:
7. SANCUSO περίληψη χαρακτηριστικών προϊόντος
8. Larkin et al, Diagnosis, assessment and management of constipation in advanced cancer ESMO clinical
practice guidelines Annals of Oncology 29 (Supplement 4) iv111–i

=== Outcome Extract 15 (Safety) ===
w 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel

=== Outcome Extract 16 (Safety) ===
Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus|
Row 4: fluoxymesterone for the treatment of cancer anorexia/cachexia. J ClinOncol. 1999;17(10):3299.|
Row 5: |
Row 6: 15. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. .ROMANA 3: a phase 3 safety extension|
Row 7: study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.AnnOncol.|
Row 8: 2017;28(8):1949.| Row 1: |
Row 2: 1. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA,|
Row 3: Lyman GH, Ogaily MS, Pirl

=== Outcome Extract 17 (Safety) ===
gitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the
Row 10: management of delirium: A comparison of efficacy, safety, and side effects. Palliat Support Care. 2015 Row 1: Νόσημα|Εμπορική ονομασία εμβολίου|Σύσταση|Χρονισμός|Παρατηρήσεις
Row 2: Γρι�πη|Fluarix, Influvac, Vaxigrip Fulcelvax, Fluad, Efluelda|Ετη�σιος εμβολιασμο�ς για ο�λους. Δυνητικα� με “ενισχυμε�νο” εμβο�λιο για τους 65 ετω�ν και α�νω|Αρχε�ς Φθινοπω�

